Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Cross Below 200-Day Moving Average - Should You Sell?

Key Points

• Shares fell below their 200‑day moving average: ELTP traded as low as $0.37 versus its 200‑day MA of $0.52 on Friday, with about 1.18 million shares changing hands.
• Solid recent quarter and profitability: the company reported $0.01 EPS on $31.59M revenue, with a net margin of 30.98% and ROE of 47.93%; market cap is roughly $399M and the P/E is 12.35.
• Business focus: Elite Pharmaceuticals is a Houston‑based specialty pharma that develops and markets branded and generic complex dosage forms—including injectables, sterile formulations and oncology therapies—while expanding via partnerships and licensing.

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.52 and traded as low as $0.37. Elite Pharmaceuticals shares last traded at $0.3704, with a volume of 1,179,674 shares trading hands.

Elite Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.44 and a current ratio of 7.34. The company has a market cap of $398.96 million, a P/E ratio of 12.35 and a beta of 0.35. The firm's fifty day moving average is $0.41 and its two-hundred day moving average is $0.52.

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. Elite Pharmaceuticals had a return on equity of 47.93% and a net margin of 30.98%.The business had revenue of $31.59 million for the quarter.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.